Mindblown: a blog about philosophy.

After-Hours Stock Movers: Arcturus Therapeutics (NASDAQ:ARCT) 14% HIGHER; reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million. Varex Imaging Corporation (NASDAQ:VREX) 10% LOWER; reported Q4 EPS of $0.45, $0.12 better than the analyst estimate of […]

(This Nov. 8 story has been corrected to say Biogen (NASDAQ:BIIB) cut profit forecast due to costs related to a deal, not the launch of its Alzheimer’s drug, in paragraph 1 and the headline) (Reuters) – Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on higher expenses related to the recent […]

After-Hours Stock Movers: Arcturus Therapeutics (NASDAQ:ARCT) 14% HIGHER; reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million. Varex Imaging Corporation (NASDAQ:VREX) 10% LOWER; reported Q4 EPS of $0.45, $0.12 better than the analyst estimate of […]

(This Nov. 8 story has been corrected to say Biogen (NASDAQ:BIIB) cut profit forecast due to costs related to a deal, not the launch of its Alzheimer’s drug, in paragraph 1 and the headline) (Reuters) – Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on higher expenses related to the recent […]

After-Hours Stock Movers: Arcturus Therapeutics (NASDAQ:ARCT) 14% HIGHER; reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million. Varex Imaging Corporation (NASDAQ:VREX) 10% LOWER; reported Q4 EPS of $0.45, $0.12 better than the analyst estimate of […]

(This Nov. 8 story has been corrected to say Biogen (NASDAQ:BIIB) cut profit forecast due to costs related to a deal, not the launch of its Alzheimer’s drug, in paragraph 1 and the headline) (Reuters) – Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on higher expenses related to the recent […]

After-Hours Stock Movers: Arcturus Therapeutics (NASDAQ:ARCT) 14% HIGHER; reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million. Varex Imaging Corporation (NASDAQ:VREX) 10% LOWER; reported Q4 EPS of $0.45, $0.12 better than the analyst estimate of […]

(This Nov. 8 story has been corrected to say Biogen (NASDAQ:BIIB) cut profit forecast due to costs related to a deal, not the launch of its Alzheimer’s drug, in paragraph 1 and the headline) (Reuters) – Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on higher expenses related to the recent […]

After-Hours Stock Movers: Arcturus Therapeutics (NASDAQ:ARCT) 14% HIGHER; reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million. Varex Imaging Corporation (NASDAQ:VREX) 10% LOWER; reported Q4 EPS of $0.45, $0.12 better than the analyst estimate of […]

(This Nov. 8 story has been corrected to say Biogen (NASDAQ:BIIB) cut profit forecast due to costs related to a deal, not the launch of its Alzheimer’s drug, in paragraph 1 and the headline) (Reuters) – Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on higher expenses related to the recent […]